Literature DB >> 24897291

Pharmacogenetics of antiepileptic drug-induced hypersensitivity.

Katarzyna M Bloch1, Graeme J Sills, Munir Pirmohamed, Ana Alfirevic.   

Abstract

Antiepileptic drugs can induce potentially life-threatening hypersensitivity reactions such as Stevens-Johnson syndrome at a frequency of one in 10,000 to one in 1000 treated patients. There is a considerable cross-reactivity among different antiepileptic drugs but the mechanisms are not known. In this review we have summarized current evidence on antiepileptic drug-induced hypersensitivity reactions and performed meta-analyses of published case-control studies that investigated associations between HLA alleles and several antiepileptic drugs in diverse populations. As the heterogeneity between studies was high, we conducted subsequent subgroup analyses and showed that HLA-B*15:02 was associated with carbamazepine, lamotrigine and phenytoin-induced Stevens-Johnson syndrome in Asian populations indicating that pretreatment testing may prevent cross-reactivity. Additionally, we explored the potential of new, high-throughput technologies that may help to understand the mechanisms and predict the risk of adverse drug reactions in the future.

Entities:  

Keywords:  HLA; antiepileptic drugs; carbamazepine; hypersensitivity reactions; lamotrigine; oxcarbazepine; pharmacogenetics; phenytoin

Mesh:

Substances:

Year:  2014        PMID: 24897291     DOI: 10.2217/pgs.14.65

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  9 in total

1.  Role of Preemptive Genotyping in Preventing Serious Adverse Drug Events in South Korean Patients.

Authors:  Grace Juyun Kim; Soo Youn Lee; Ji Hye Park; Brian Y Ryu; Ju Han Kim
Journal:  Drug Saf       Date:  2017-01       Impact factor: 5.606

2.  Genotypes at rs2844682 and rs3909184 have no clinical value in identifying HLA-B*15:02 carriers.

Authors:  Guang-Dan Zhu; Ashley A Brenton; Alka Malhotra; Bae J Riley; Katherine E Church; Frank G Espin; Tanya A Moreno; Jennifer M Strickland; Andria L Del Tredici
Journal:  Eur J Clin Pharmacol       Date:  2015-06-04       Impact factor: 2.953

3.  Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines.

Authors:  Lisanne E N Manson; Jesse J Swen; Henk-Jan Guchelaar
Journal:  Front Pharmacol       Date:  2020-09-23       Impact factor: 5.810

4.  PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.

Authors:  Julia M Barbarino; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2015-04       Impact factor: 2.089

Review 5.  Genetic Basis of Delayed Hypersensitivity Reactions to Drugs in Jewish and Arab Populations.

Authors:  Mohammed Aboukaoud; Shoshana Israel; Chaim Brautbar; Sara Eyal
Journal:  Pharm Res       Date:  2018-09-17       Impact factor: 4.200

Review 6.  Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection.

Authors:  Alfredo B Cuéllar-Barboza; Susan L McElroy; Marin Veldic; Balwinder Singh; Simon Kung; Francisco Romo-Nava; Nicolas A Nunez; Alejandra Cabello-Arreola; Brandon J Coombes; Miguel Prieto; Hannah K Betcher; Katherine M Moore; Stacey J Winham; Joanna M Biernacka; Mark A Frye
Journal:  Int J Bipolar Disord       Date:  2020-07-04

7.  HLA-A*11:01 is associated with levetiracetam-induced psychiatric adverse events.

Authors:  Tae-Won Yang; Jangsup Moon; Tae-Joon Kim; Jin-Sun Jun; Jung-Ah Lim; Soon-Tae Lee; Keun-Hwa Jung; Kyung-Il Park; Ki-Young Jung; Kon Chu; Sang Kun Lee
Journal:  PLoS One       Date:  2018-07-18       Impact factor: 3.240

8.  Evidence used in model-based economic evaluations for evaluating pharmacogenetic and pharmacogenomic tests: a systematic review protocol.

Authors:  Jaime L Peters; Chris Cooper; James Buchanan
Journal:  BMJ Open       Date:  2015-11-11       Impact factor: 2.692

9.  A web resource for mining HLA associations with adverse drug reactions: HLA-ADR.

Authors:  Gurpreet S Ghattaoraya; Yenal Dundar; Faviel F González-Galarza; Maria Helena Thomaz Maia; Eduardo José Melo Santos; Andréa Luciana Soares da Silva; Antony McCabe; Derek Middleton; Ana Alfirevic; Rumona Dickson; Andrew R Jones
Journal:  Database (Oxford)       Date:  2016-05-17       Impact factor: 3.451

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.